|
1
|
Reporting recommendations for tumor marker prognostic studies (REMARK).
|
J Natl Cancer Inst
|
2005
|
9.38
|
|
2
|
Reporting recommendations for tumor marker prognostic studies.
|
J Clin Oncol
|
2005
|
6.31
|
|
3
|
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
|
J Clin Oncol
|
2004
|
5.08
|
|
4
|
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
|
J Natl Cancer Inst
|
2003
|
4.45
|
|
5
|
REporting recommendations for tumor MARKer prognostic studies (REMARK).
|
Breast Cancer Res Treat
|
2006
|
4.42
|
|
6
|
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
|
Breast Cancer Res
|
2004
|
3.90
|
|
7
|
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
|
J Clin Oncol
|
2003
|
3.58
|
|
8
|
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual.
|
Surg Clin North Am
|
2003
|
2.82
|
|
9
|
REporting recommendations for tumor MARKer prognostic studies (REMARK).
|
Nat Clin Pract Oncol
|
2005
|
2.82
|
|
10
|
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.
|
Mod Pathol
|
2004
|
2.39
|
|
11
|
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.
|
Cancer Res
|
2003
|
2.01
|
|
12
|
REporting recommendations for tumour MARKer prognostic studies (REMARK).
|
Eur J Cancer
|
2005
|
1.93
|
|
13
|
Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
|
Cancer Res
|
2002
|
1.91
|
|
14
|
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
|
Cancer
|
2003
|
1.87
|
|
15
|
Hazard rates of recurrence following diagnosis of primary breast cancer.
|
Breast Cancer Res Treat
|
2005
|
1.85
|
|
16
|
Effects of smoking on the pharmacokinetics of erlotinib.
|
Clin Cancer Res
|
2006
|
1.74
|
|
17
|
REporting recommendations for tumor MARKer prognostic studies (REMARK).
|
Nat Clin Pract Urol
|
2005
|
1.72
|
|
18
|
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
|
Clin Cancer Res
|
2006
|
1.67
|
|
19
|
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
|
J Clin Oncol
|
2008
|
1.57
|
|
20
|
Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome.
|
Cancer
|
2002
|
1.41
|
|
21
|
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.
|
J Natl Cancer Inst
|
2009
|
1.31
|
|
22
|
Maspin expression in invasive breast cancer: association with other prognostic factors.
|
J Pathol
|
2003
|
1.25
|
|
23
|
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.
|
Breast Cancer Res Treat
|
2005
|
0.88
|
|
24
|
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
|
Clin Cancer Res
|
2002
|
0.87
|
|
25
|
Real-time quantitative analysis of telomerase activity in breast tumor specimens using a highly specific and sensitive fluorescent-based assay.
|
Diagn Mol Pathol
|
2002
|
0.86
|
|
26
|
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
|
Breast Cancer Res Treat
|
2005
|
0.79
|
|
27
|
Pharmacy team providing enhanced services to a transitional care unit.
|
Am J Health Syst Pharm
|
2007
|
0.75
|